Share: Dallan Murray named chief commercial officer Louise Rodino-Klapac, Ph.D., named chief scientific officer Ty Howton, general counsel, to retire from Sarepta Ryan Brown named interim general counsel
CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today its board of directors approved the appointments of several executive leadership positions: Ian Estepan to executive vice president and chief financial officer, Dallan Murray to senior vice president and chief commercial officer, and Louise Rodino-Klapac, Ph.D., to executive vice president and chief scientific officer, effective today. Both Mr. Estepan and Dr. Rodino-Klapac will continue to serve as members of the company s executive committee (ECOM). Mr. Murray will become a member of the Company s ECOM. Sarepta also announced the retirement of Ty Howton, executive vice president and general coun
More people needing stroke treatments after Christchurch terror attack
stuff.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stuff.co.nz Daily Mail and Mail on Sunday newspapers.
COVID-19 Neurologic Fallout Not Limited to the Severely Ill
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
If You Have These 2 Subtle Symptoms, There s a Good Chance You Have COVID
By Lauren Gray of Best Life |
If You Have These 2 Subtle Symptoms, There s a Good Chance You Have COVID
Most COVID symptoms are ambiguous: a cough, fever, or sore throat could yield any diagnosis from the flu to bronchitis. But scientists say that two subtle symptoms are now considered a dead giveaway that you re destined for a COVID test. Those symptoms are
ageusia and
One study published this week in
Neurology Clinical Practice, a journal of the American Academy of Neurology, found that 63 percent of COVID patients admitted to a hospital in Udine, Italy experienced this particular set of symptoms. Among those patients, 22 percent reported that their loss of olfactory senses was the first sign of sickness. Those symptoms lasted for between 25 and 30 days on average.